cytarabine has been researched along with Infections, Coronavirus in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Angelov, D; Cotter, AG; Fay, M; Lambert, JS; McGettrick, P; McGinty, T; O'Kelly, B; Sheehan, G | 1 |
| Bar-Natan, M; Lancman, G; Mascarenhas, J | 1 |
2 other study(ies) available for cytarabine and Infections, Coronavirus
| Article | Year |
|---|---|
Outcome of a patient with refractory Hodgkin lymphoma on pembrolizumab, infected with SARS-CoV-2.
Topics: Adult; Anti-Bacterial Agents; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Betacoronavirus; Bleomycin; Coronavirus Infections; COVID-19; Cyclophosphamide; Cytarabine; Dacarbazine; Doxorubicin; Etoposide; Female; Hodgkin Disease; Humans; Hydroxychloroquine; Idarubicin; Mediastinal Neoplasms; Pandemics; Pneumonia, Viral; Positron-Emission Tomography; Prednisone; Procarbazine; SARS-CoV-2; Treatment Outcome; Vinblastine; Vincristine | 2020 |
Severe COVID-19 virus reactivation following treatment for B cell acute lymphoblastic leukemia.
Topics: Acute Disease; Antibodies, Viral; Anticoagulants; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; COVID-19 Serotherapy; Cytarabine; Female; Humans; Immunization, Passive; Immunosuppressive Agents; Middle Aged; Pandemics; Pneumonia, Viral; Polymerase Chain Reaction; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Rituximab; SARS-CoV-2; Steroids; Treatment Outcome | 2020 |